100010001000543559575420585240000400004000040000sbbp:AccruedLiabilitiesAndOtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent0001634432--12-312020Q2false0.0675100000000001634432srt:MaximumMemberus-gaap:CommonStockMember2019-04-012019-06-300001634432srt:MaximumMemberus-gaap:CommonStockMember2019-01-012019-06-300001634432us-gaap:CommonStockMember2020-04-012020-06-300001634432us-gaap:CommonStockMember2020-01-012020-06-300001634432us-gaap:RetainedEarningsMember2020-06-300001634432us-gaap:AdditionalPaidInCapitalMember2020-06-300001634432us-gaap:RetainedEarningsMember2020-03-310001634432us-gaap:AdditionalPaidInCapitalMember2020-03-310001634432us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100016344322020-03-310001634432us-gaap:RetainedEarningsMember2019-12-310001634432us-gaap:AdditionalPaidInCapitalMember2019-12-310001634432us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001634432us-gaap:RetainedEarningsMember2019-06-300001634432us-gaap:AdditionalPaidInCapitalMember2019-06-300001634432us-gaap:RetainedEarningsMember2019-03-310001634432us-gaap:AdditionalPaidInCapitalMember2019-03-3100016344322019-03-310001634432us-gaap:RetainedEarningsMember2018-12-310001634432us-gaap:AdditionalPaidInCapitalMember2018-12-310001634432us-gaap:CommonStockMember2020-06-300001634432sbbp:DeferredSharesMember2020-06-300001634432us-gaap:CommonStockMember2020-03-310001634432sbbp:DeferredSharesMember2020-03-310001634432us-gaap:CommonStockMember2019-12-310001634432sbbp:DeferredSharesMember2019-12-310001634432us-gaap:CommonStockMember2019-06-300001634432sbbp:DeferredSharesMember2019-06-300001634432us-gaap:CommonStockMember2019-03-310001634432sbbp:DeferredSharesMember2019-03-310001634432us-gaap:CommonStockMember2018-12-310001634432sbbp:DeferredSharesMember2018-12-310001634432sbbp:NovoNordiskHealthcareAgMemberus-gaap:CommonStockMember2018-12-3100016344322019-01-012019-12-310001634432sbbp:NonEmployeeDirectorEquityCompensationPlanMember2020-06-300001634432sbbp:InducementPlan2017Member2020-06-300001634432sbbp:EquityCompensationPlan2015Member2020-06-300001634432us-gaap:EmployeeStockOptionMember2019-01-012019-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2019-12-310001634432sbbp:EmployeeMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001634432srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001634432us-gaap:RoyaltyMember2020-04-012020-06-300001634432us-gaap:ProductMember2020-04-012020-06-300001634432us-gaap:RoyaltyMember2020-01-012020-06-300001634432us-gaap:ProductMember2020-01-012020-06-300001634432us-gaap:RoyaltyMember2019-04-012019-06-300001634432us-gaap:ProductMember2019-04-012019-06-300001634432us-gaap:RoyaltyMember2019-01-012019-06-300001634432us-gaap:ProductMember2019-01-012019-06-300001634432sbbp:KeveyisMembersbbp:AcquiredDevelopedProductRightsMember2017-03-012017-03-310001634432us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001634432us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001634432us-gaap:RetainedEarningsMember2020-04-012020-06-300001634432us-gaap:RetainedEarningsMember2020-01-012020-06-300001634432us-gaap:RetainedEarningsMember2019-04-012019-06-300001634432us-gaap:RetainedEarningsMember2019-01-012019-06-300001634432sbbp:TermLoanAgreementThirdLoanMember2020-05-190001634432sbbp:TermLoanAgreementSecondLoanMember2020-05-190001634432us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300001634432us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001634432sbbp:KeveyisMember2020-06-300001634432sbbp:KeveyisMember2019-12-310001634432us-gaap:WarrantMember2020-06-300001634432us-gaap:WarrantMember2019-12-310001634432us-gaap:WarrantMember2020-01-012020-06-300001634432us-gaap:EmployeeStockOptionMember2020-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2020-06-300001634432us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001634432us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersbbp:StrongbridgeIrelandLtdMember2018-12-310001634432sbbp:TermLoanAgreementMemberus-gaap:BaseRateMember2020-05-190001634432sbbp:TermLoanAgreementMember2020-06-300001634432sbbp:TermLoanAgreementInitialLoanMember2020-05-190001634432srt:MaximumMembersbbp:TermLoanAgreementMember2020-05-190001634432sbbp:TermLoanAgreementMemberus-gaap:PrimeRateMember2020-05-192020-05-190001634432sbbp:TermLoanAgreementMemberus-gaap:BaseRateMember2020-05-192020-05-190001634432sbbp:KeveyisMembersbbp:AcquiredDevelopedProductRightsMember2020-06-300001634432sbbp:WarrantsIssuedAvenueCapitalLoanAgreementMember2020-06-300001634432srt:MaximumMembersbbp:WarrantsIssuedAvenueCapitalLoanAgreementMember2020-06-300001634432sbbp:WarrantsIssuedPrivateEquityPlacementFacilityMember2020-06-300001634432sbbp:WarrantsIssuedLoanAgreementOneMember2020-06-300001634432sbbp:WarrantsIssuedCrgCreditFacilityMember2020-06-300001634432sbbp:WarrantsIssuedCrgCreditFacilityAmendmentMember2020-06-300001634432sbbp:WarrantsIssuedAvenueCapitalLoanAgreementMember2020-05-1900016344322019-06-3000016344322018-12-310001634432us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300001634432us-gaap:FairValueMeasurementsRecurringMember2020-06-300001634432us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001634432us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001634432us-gaap:FairValueMeasurementsRecurringMember2019-12-310001634432us-gaap:WarrantMember2020-01-012020-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001634432us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001634432us-gaap:WarrantMember2019-01-012019-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300001634432us-gaap:EmployeeStockOptionMember2019-01-012019-06-300001634432sbbp:KeveyisMember2020-01-012020-06-300001634432us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300001634432us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300001634432us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001634432us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001634432us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2019-04-012019-06-300001634432us-gaap:ResearchAndDevelopmentExpenseMember2019-04-012019-06-300001634432us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300001634432us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300001634432us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001634432us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000016344322020-04-012020-06-300001634432us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001634432us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001634432us-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-300001634432sbbp:Covid19CaresActMember2020-06-300001634432sbbp:WarrantsIssuedCrgCreditFacilityMember2020-01-012020-06-300001634432sbbp:WarrantsIssuedCrgCreditFacilityAmendmentMember2020-01-012020-06-300001634432sbbp:WarrantsIssuedAvenueCapitalLoanAgreementMember2020-01-012020-06-300001634432sbbp:WarrantsIssuedPrivateEquityPlacementFacilityMember2020-01-012020-06-300001634432sbbp:WarrantsIssuedLoanAgreementOneMember2020-01-012020-06-300001634432us-gaap:CommonStockMember2019-04-012019-06-300001634432us-gaap:CommonStockMember2019-01-012019-06-300001634432sbbp:NovoNordiskHealthcareAgMemberus-gaap:CommonStockMember2018-12-012018-12-310001634432us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001634432srt:MaximumMember2020-01-012020-06-300001634432sbbp:NovoNordiskHealthcareAgMember2019-12-012019-12-310001634432sbbp:NovoNordiskIncMembersbbp:ServicesAgreementMember2018-12-012018-12-310001634432sbbp:WarrantsIssuedAvenueCapitalLoanAgreementMember2020-05-192020-05-1900016344322019-04-012019-06-300001634432sbbp:TermLoanAgreementMember2020-05-190001634432srt:MinimumMembersbbp:TermLoanAgreementMember2020-05-192020-05-190001634432srt:MaximumMembersbbp:TermLoanAgreementMember2020-05-192020-05-190001634432sbbp:TermLoanAgreementMember2020-05-192020-05-190001634432sbbp:KeveyisMembersbbp:AcquiredDevelopedProductRightsMember2016-12-012016-12-310001634432sbbp:KeveyisMembersbbp:AcquiredDevelopedProductRightsMember2016-12-3100016344322020-06-3000016344322019-12-3100016344322019-01-012019-06-3000016344322020-07-2800016344322020-01-012020-06-30sbbp:segmentxbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharessbbp:itemsbbp:employeesbbp:installmentsbbp:customersbbp:product

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the Transition Period from _____________ to _____________

Commission file number 001-37569

Strongbridge Biopharma plc

(Exact name of Registrant as specified in its charter)

Ireland

 

98-1275166

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

Registrant’s Telephone Number, Including Area Code: +1 610-254-9200

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of each class:

    

Trading Symbol

    

Name of each exchange on which registered:

Ordinary shares, par value $0.01 per share

SBBP

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

 

 

 

 

Non-Accelerated Filer

Smaller Reporting Company

 

 

 

 

 

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of July 28, 2020, there were 54,355,957 ordinary shares of the registrant issued and outstanding.  

Table of Contents

TABLE OF CONTENTS

 

 

Page

PART I.

Financial Information

1

 

 

Item 1.

Financial Statements

1

 

Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

1

 

Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2020 and 2019

2

 

Consolidated Statements of Stockholders’ Equity

3

 

Consolidated Statements of Cash Flow for the Six Months Ended June 30, 2020 and 2019

4

 

Notes to the Unaudited Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

 

 

PART II.

Other Information

24

 

 

Item 1.

Legal Proceedings

24

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 3.

Defaults Upon Senior Securities

27

Item 4.

Mine Safety Disclosures

27

Item 5.

Other Information

27

Item 6.

Exhibits

28

SIGNATURES

29

Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are referred to without the ® and symbols, but absence of such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. The trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners.

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

STRONGBRIDGE BIOPHARMA plc

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)

June 30, 

    

December 31, 

    

2020

2019

ASSETS

Current assets:

Cash and cash equivalents

$

59,909

$

57,032

Marketable securities

21,072

Accounts receivable

2,885

2,289

Inventory

1,315

1,993

Prepaid expenses and other current assets

 

1,914

 

1,157

Total current assets

 

66,023

 

83,543

Property and equipment, net

 

248

 

291

Right of use asset, net

696

789

Intangible asset, net

 

22,599

 

25,110

Goodwill

 

7,256

 

7,256

Other assets

 

812

 

649

Total assets

$

97,634

$

117,638

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

1,957

$

3,331

Accrued and other current liabilities

 

17,363

 

20,962

Current portion of long-term debt, net

 

162

 

Total current liabilities

 

19,482

 

24,293

Long-term debt, net

6,841

Warrant liability

10,914

4,127

Supply agreement liability, noncurrent

11,556

15,947

Other long-term liabilities

972

1,080

Total liabilities

 

49,765

 

45,447

Commitments and contingencies (Note 8)

Stockholders’ equity:

Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at June 30, 2020 and December 31, 2019

44

44

Ordinary shares, $0.01 par value, 600,000,000 shares authorized; 54,355,957 and 54,205,852 shares issued and outstanding at June 30, 2020 and December 31, 2019

 

544

 

542

Additional paid-in capital

 

337,734

 

332,085

Accumulated deficit

 

(290,453)

 

(260,483)

Accumulated other comprehensive income

3

Total stockholders’ equity

 

47,869

 

72,191

Total liabilities and stockholders’ equity

$

97,634

$

117,638

The accompanying notes are an integral part of these unaudited consolidated financial statements.

1

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)

Three Months Ended

Six Months Ended

June 30

June 30, 

    

2020

    

2019

    

2020

    

2019

    

Revenues:

Net product sales

$

7,752

$

6,073

$

14,415

$

10,406

Royalty revenue

8

6

19

16

Total revenues

7,760

6,079

14,434

10,422

Cost and expenses:

Cost of sales (excluding amortization of intangible asset)

$

393

$

1,022

$

1,362

$

1,835

Selling, general and administrative

9,638

12,182

20,041

24,282

Research and development

 

6,152

 

8,739

 

13,704

 

15,322

Amortization of intangible asset

1,255

1,255

2,511

2,511

Total cost and expenses

 

17,438

 

23,198

 

37,618

 

43,950

Operating loss

 

(9,678)

 

(17,119)

 

(23,184)

 

(33,528)

Other (expense) income, net:

Unrealized (loss) gain on fair value of warrants

(7,367)

8,697

(6,787)

6,877

Income from field services agreement

1,725

3,741

Expense from field services agreement

(1,758)

(3,987)

Interest expense

(253)

(253)

Other income, net

 

26

 

608

 

254

 

1,293

Total other (expense) income, net

 

(7,594)

 

9,272

 

(6,786)

 

7,924

Loss before income taxes

 

(17,272)

 

(7,847)

 

(29,970)

 

(25,604)

Income tax expense

 

 

(400)

 

 

(1,077)

Net loss

$

(17,272)

$

(8,247)

 

(29,970)

 

(26,681)

Other comprehensive income

 

 

 

Unrealized loss on marketable securities

(6)

(3)

Comprehensive loss

$

(17,278)

$

(8,247)

$

(29,973)

$

(26,681)

Net loss attributable to ordinary shareholders:

Basic

$

(17,272)

$

(8,247)

$

(29,970)

$

(26,681)

Diluted

$

(17,272)

$

(16,944)

$

(29,970)

$

(33,558)

Net loss per share attributable to ordinary shareholders:

Basic

$

(0.32)

$

(0.15)

$

(0.55)

$

(0.49)

Diluted

$

(0.32)

$

(0.30)

$

(0.55)

$

(0.60)

Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:

Basic

54,302,325

 

54,175,731

 

54,266,675

 

54,165,439

Diluted

54,302,325

55,781,078

 

54,266,675

 

56,262,936

The accompanying notes are an integral part of these unaudited consolidated financial statements.

2

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Consolidated Statement of Stockholders’ Equity

(In thousands, except share amounts)

(unaudited)

 

    

    

Additional

    

    

Accumulated Other

    

Total

 

Ordinary Shares

Deferred Shares

Paid-In

Accumulated

Comprehensive

Shareholders’

 

Shares

    

Amount

    

Shares

    

Amount

    

Capital

Deficit

Gain

Equity

 

Balance—March 31, 2019

54,167,948

$

542

40,000

$

44

$

325,863

$

(229,466)

$

96,983

Net loss

(8,247)

(8,247)

Stock-based compensation

2,572

2,572

Exercise of stock options

4,113

*

12

12

Ordinary shares issued, net of shares withheld for employee taxes

14,207

*

(31)

(31)

Balance—June 30, 2019

54,186,268

$

542

40,000

$

44

$

328,416

$

(237,713)

$

91,289

Balance—December 31, 2018

54,122,074

$

541

40,000

$

44

$

323,402

$

(211,032)

$

112,955

Net loss

(26,681)

(26,681)

Stock-based compensation

4,895

4,895

Exercise of stock options

43,841

1

178

179

Ordinary shares issued, net of shares withheld for employee taxes

20,353

*

(59)

(59)

Balance—June 30, 2019

54,186,268

$

542

40,000

$

44

$

328,416

$

(237,713)

$

91,289

Balance—March 31, 2020

54,247,501

$

542

40,000

$

44

$

333,768

$

(273,181)

6

$

61,179

Net loss

(17,272)

(17,272)

Stock-based compensation

1,773

1,773

Issuance of warrants and beneficial conversion feature related to the Loan Agreement

2,457

2,457

Ordinary shares issued, net of shares withheld for employee taxes

108,456

2

(264)

(262)

Unrealized loss on marketable securities

(6)

(6)

Balance—June 30, 2020

54,355,957

$

544

40,000

$

44

$

337,734

$

(290,453)

$

47,869

Balance—December 31, 2019

54,205,852

$

542

40,000

$

44

$

332,085

$

(260,483)

3

$

72,191

Net loss

(29,970)

(29,970)

Stock-based compensation

3,524

3,524

Issuance of warrants and beneficial conversion feature related to the Loan Agreement

2,457

2,457

Ordinary shares issued, net of shares withheld for employee taxes

150,105

2

(332)

(330)

Unrealized loss on marketable securities

(3)

(3)

Balance—June 30, 2020

54,355,957

$

544

40,000

$

44

$

337,734

$

(290,453)

$

47,869

* Represents an amount less than $1.

3

Table of Contents

The accompanying notes are an integral part of these unaudited consolidated financial statements.

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Cash Flow

(In thousands)

(unaudited)

Six Months Ended

June 30, 

2020

2019

Cash flows from operating activities:

Net loss

$

(29,970)

$

(26,681)

Adjustments to reconcile net loss to net cash used in operating activities:

Change in fair value of warrant liability

6,787

(6,877)

Stock-based compensation

 

3,524

 

4,895

Amortization of intangible asset

2,511

2,511

Accretion of discounts on marketable securities

(53)

(71)

Depreciation

 

43

 

36

Changes in operating assets and liabilities:

Accounts receivable

(596)

(4,717)

Inventory

294

393

Prepaid expenses and other current assets

 

(757)

 

1,782

Other assets

314

(1,166)

Accounts payable

 

(1,374)

 

285

Accrued and other liabilities

(8,098)

(6,873)

Net cash used in operating activities

 

(27,375)

 

(36,483)

Cash flows from investing activities:

Purchases of property and equipment

 

 

(33)

Purchases of marketable securities

(27,939)

Maturities of marketable securities

21,122

Net cash provided by (used in) investing activities

 

21,122

 

(27,972)

Cash flows from financing activities:

Proceeds from long-term debt, net

9,460

Proceeds from exercise of stock options

180

Payments related to tax withholding for net-share settled equity awards

(330)

(59)

Net cash provided by financing activities

 

9,130

 

121

Net increase (decrease) in cash and cash equivalents

 

2,877

 

(64,334)

Cash and cash equivalents—beginning of period

 

57,032

 

122,490

Cash and cash equivalents—end of period

$

59,909

$

58,156

Supplemental disclosures of cash flow information:

Cash paid during the year for:

 

 

Interest

$

118

$

Income taxes other, net of refunds

$

531

$

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Notes to Unaudited Consolidated Financial Statements

1. Organization

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (the “FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.

We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation, such as acromegaly. Both levoketoconazole and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”).

In January 2018, Strongbridge Ireland Limited, one of our wholly-owned subsidiaries, acquired the U.S. and Canadian rights to Macrilen (macimorelin), the first and only oral drug approved by the FDA for the diagnosis of patients with adult growth hormone deficiency. We launched Macrilen in the United States in July 2018. In December 2018, we sold Strongbridge Ireland Limited to Novo Nordisk Healthcare AG (“Novo”) for $145 million plus the right to receive tiered royalties on net sales of Macrilen through 2027. In addition, Strongbridge U.S. Inc., another of our wholly-owned subsidiaries, entered into an agreement with Novo Nordisk Inc. (“NNI”), a subsidiary of Novo, pursuant to which NNI funded the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years. Novo also purchased 5.2 million of our ordinary shares at a purchase price of $7.00 per share. In December 2019, we reached an agreement with Novo to terminate the services agreement. We received a $6 million payment in connection with such termination and we no longer provide services to Novo.

Liquidity

We believe that our cash and cash equivalents of $59.9 million at June 30, 2020, will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of these unaudited consolidated financial statements.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We plan to continue to fund our operations and capital funding needs through equity or debt financing along with revenues from Keveyis. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated

5

Table of Contents

financial statements. Actual results could differ from those estimates. Results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission on February 28, 2020 (the “2019 Annual Report”). Our significant accounting policies are described in Note 2 of the notes to the audited consolidated financial statements included in our 2019 Annual Report. Since the date of those financial statements, there have been no changes to our significant accounting policies.

Reclassifications

The consolidated financial statements contain certain reclassifications within our consolidated statements of cash flow for the six months ended June 30, 2019 due to an immaterial incorrect classification of investments in marketable securities and the related impact on investing activities.

Leases

We account for leases in accordance with Accounting Standards Codification Topic 842, Leases (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) we have the right to control the use of the identified asset.

Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Accrued and other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date.

Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments.

The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

6

Table of Contents

We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all of our other leases.

Cash, cash equivalents and marketable securities

We consider all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents consist of account balances at banks and money market accounts, respectively.

We occasionally invest our excess cash balances in marketable debt securities of highly rated financial institutions. We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. We classify marketable debt securities as available-for-sale and, accordingly, record such securities at fair value. We classify these securities as current assets as these investments are intended to be available to us for use in funding current operations. There were no marketable securities as of June 30, 2020.

Unrealized gains and losses on marketable debt securities are recorded as a separate component of Accumulated other comprehensive income (loss) included in stockholders’ equity.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment.

Net loss per share

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted-average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti-dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units (“RSUs”) and equity-classified warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of June 30, 2020 and 2019, as they would be anti-dilutive:

June 30, 

2020

2019

Warrants

7,100,643

1,803,253

Stock options issued and outstanding

    

10,499,222

10,241,158

Unvested RSUs

1,090,300

964,850

Recent accounting pronouncements – not yet adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the

7

Table of Contents

current other-than-temporary impairment model. The standard is effective for smaller reporting companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. We do not expect the adoption of this standard to have a significant impact on our financial statements or internal controls.

3. Revenue recognition

Product sales, net

We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, most of whom are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of the product to the Customer. Transfer of control occurs upon receipt of the product by the Customer. We expense incremental costs related to the set-up of contracts with the Customer when incurred, as these costs do not meet the criteria for capitalization.

Reserves for variable consideration

Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in Selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the Customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates for the estimated patient mix. These reserves are recorded in the same

8

Table of Contents

period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Manufacturers of pharmaceutical products are responsible for 70% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that have been recognized as revenue, but remains in the Customer’s inventory at the end of each reporting period.

Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while there is a determination of the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to uninsured patients who satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

4. Fair value measurement

We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows: 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases and decreases in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement.

We did not have any transfers between the different levels.

9

Table of Contents

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):

As of June 30, 2020

 

Level I

Level II

Level III

Total

 

Cash equivalents

58,966

58,966

Marketable securities

Total assets

$

58,966

$

$

$

58,966

Warrant liability

10,914

10,914

Total liabilities

$

$

$

10,914

$

10,914

As of December 31, 2019

 

Level I

Level II

Level III

Total

 

Cash equivalents

56,544

56,544

Marketable securities

21,072

21,072

Total assets

$

56,544

$

21,072

$

$

77,616

Warrant liability

4,127

4,127

Total liabilities

$

$

$

4,127

$

4,127

The following table presents a reconciliation of our level 3 warrant liability (in thousands):

    

As of June 30, 2020

Balance as of December 31, 2019

$

4,127

Unrealized loss on fair value of warrants for six months ended June 30, 2020

6,787

Balance as of June 30, 2020

$

10,914

5. Intangible asset and goodwill

The following represents the balance of our intangible asset and goodwill as follows (in thousands):

As of June 30, 2020

 

Beginning of Period

Amortization

End of Period

 

Keveyis

$

25,110

$

(2,511)

$

22,599

Goodwill

 

7,256

 

7,256

Total

$

32,366

$

(2,511)

$

29,855

Our finite-lived intangible asset consists of acquired developed product rights obtained from our acquisition of Keveyis (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).

Pursuant to the terms of the Asset Purchase Agreement and Supply Agreement that we entered into with Taro in December 2016, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets.  Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. We have concluded that the supply price payable by us exceeds fair value and, therefore, have used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability is being reduced as we purchase inventory over the term of the Supply Agreement that we entered into with Taro.  In addition, we incurred transaction costs of $2.4 million. The transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of $1.3 million and $2.5 million for the three and six months ended June 30, 2020 and 2019, respectively.

10

Table of Contents

6. Long-term debt

On May 19, 2020 (the “Closing Date”), Strongbridge Biopharma plc (“Strongbridge”), along with Strongbridge U.S. Inc., Cortendo AB (publ) and Strongbridge Dublin Limited, each a subsidiary of Strongbridge (the “Subsidiaries,” and together with Strongbridge, the “Company”), entered into a $30 million Term Loan Agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund L.P. (“Avenue”), as administrative agent and collateral agent, and the lenders named therein and from time to time a party thereto (the “Lenders”). Pursuant to the terms of the Loan Agreement, Strongbridge U.S. Inc. (the “Borrower”) borrowed $10 million (the “Initial Loan”) from the Lenders at closing.  

The Borrower may borrow up to two additional tranches of $10 million under the Loan Agreement. The first $10 million tranche (the “Second Loan”) is available between October 1, 2020 and December 31, 2020 if Strongbridge achieves positive top-line data for RECORLEV in its Phase 3 LOGICS clinical trial. The second $10 million tranche (the “Third Loan” and, together with the Initial Loan and the Second Loan, the “Loans”) is available between October 1, 2021 and March 31, 2022 if Strongbridge achieves FDA approval of RECORLEV and subject to Avenue’s investment committee approval.  

The Loan Agreement has a four-year term, no minimum revenue or cash balance financial covenants and an interest-only period of up to 36 months assuming the Company achieves positive top-line data for RECORLEV in its Phase 3 LOGICS clinical trial and the Company receives FDA approval of RECORLEV. The Borrower paid a commitment fee of $200,000 (1% of the amounts of the Initial Loan and the Second Loan).

Amounts borrowed under the Loan Agreement accrue interest at a floating rate per annum (based on a year of 365 days) equal to the sum of (a) the greater of (x) the Prime Rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (y) 3.25%, plus (b) 6.75%. Accrued interest is payable in advance on the first day of each month and on the maturity date; provided however that no principal payments are required for the first 12 months (which the period is extended for up to 36 months subject to the satisfaction of certain conditions under the Loan Agreement). The Borrower is also required to pay the Lenders a final payment fee upon repayment or prepayment of the Loans in accordance with the terms and conditions of the Loan Agreement. The interest rate as of June 30, 2020 was 10%.

The Borrower may prepay all or a portion of the outstanding principal amount of any Loans outstanding under the Loan Agreement at any time upon prior notice to the Lenders subject to a prepayment premium (which reduces after the first year) and the payment of the pro rata portion of the final payment fee (to the extent not already paid) based on the amount of Loans being prepaid. In certain circumstances, including a change of control and certain asset sales or licensing transactions, the Borrower may be required to prepay all or a portion of the Loans outstanding, and, to the extent required under the terms of the Loan Agreement, the applicable prepayment premium and final payment fee.

In connection with the execution of the Loan Agreement, Strongbridge issued warrants to the Lenders to purchase an aggregate of 267,390 ordinary shares at an exercise price (the “Exercise Price”) equal to the lower of (i) $1.87 (which is equal to the five-day volume weighted average price as of the trading day immediately prior to execution of the financing agreement) or (ii) the effective price of any bona fide equity financing prior to December 31, 2020 (subject to certain adjustments described in the Warrant).  The Warrant will be exercisable, in full or in part, at any time prior to five years following the issue date and contains customary provisions for assumption or exchange upon a change of control or a sale of all or substantially all of the assets of the Company. We have accounted for these warrants as equity, and the fair value is recorded into Additional paid-in capital.

Avenue has the right to convert up to $3 million of the aggregate principal amount of any loans outstanding under the Loan Agreement into Strongbridge ordinary shares at a price per share of the lower of (a) $2.24, or (b) 20% above the effective price of any bona fide equity financing of Strongbridge prior to December 31, 2020, subject to the terms and conditions described in the Loan Agreement. We have accounted for this beneficial conversion feature, and the fair value is recorded into Additional paid-in capital.

11

Table of Contents

Future principal payments due under the Loan Agreement, if the interest payment only period is not extended are as follows (in thousands):

    

Principal

 

Payments

 

2020

 

2021

1,944

2022

3,333

2023

3,333

2024

1,390

Total future payments

$

10,000

7. Accrued and other current liabilities

Accrued and other current liabilities consist of the following (in thousands):

June 30, 

December 31, 

 

2020

2019

 

Consulting and professional fees

$

4,934

$

4,335

Supply agreement - current portion

4,391

2,773

Accrued sales allowances

2,350

2,990

Employee compensation

2,511

4,452

Accrued taxes

1,361

1,892

Severance

580

2,968

Lease liability - current portion

394

374

Accrued royalties

301

806

Other

 

541

 

372

Total accrued and other current liabilities

$

17,363

$

20,962

8. Commitments and contingencies

(a) Commitments to Taro Pharmaceuticals Industries Ltd.

In December 2016, we acquired the U.S. marketing rights to Keveyis (dichlorphenamide) from Taro. Under the terms of the Asset Purchase Agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. As of June 30, 2020, our remaining obligation was $19.0 million. Our Supply Agreement with Taro may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. We are also required to reimburse Taro for its royalty obligation resulting from its sale of Keveyis to us.

(b) Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction, such as breaches of contracts, unfavorable tax consequences and employee liabilities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss and such amount could be material to our consolidated financial statements. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall

12

Table of Contents

maximum amount of the obligation under such indemnifications cannot be reasonably estimated. However, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable at this time.

9. Taxes

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized.

We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed.

We did not incur income any tax expense for the three and six months ended June 30, 2020.

CARES Act

The CARES Act allows companies to defer payments of employer Social Security payroll taxes that are otherwise owed for wage payments made after March 27, 2020 through December 31, 2020. Fifty percent of the taxes deferred are required to be paid by December 31, 2021 with the remaining fifty percent required to be paid by December 31, 2022. As of June 30, 2020, we have accrued $100,000 of Social Security payroll taxes that will be deferred under the CARES Act. We expect to continue to defer payroll taxes through the end of the year and pay them as described above.

10. Warrants

Warrants

Our outstanding warrants as of June 30, 2020 are as follows:

    

    

    

Warrants

 

Outstanding

Exercise

    

Expiration

    

Warrants

    

Warrants

June 30, 

Classification

Price

Date

Issued

Exercised

2020

Warrants in connection with private equity placement

    

Liability

    

$

2.50

    

6/28/2022

    

7,000,000

(1,970,000)

5,030,000

Warrants in connection with Horizon and Oxford loan agreement

Equity

$

2.45

12/28/2026